US FDA calls foul on Abbott for Kaletra promotional video
This article was originally published in Scrip
A promotional video for Abbott's antiretroviral Kaletra (lopinavir plus ritonavir) minimises the drug's risks, overstates its efficacy and includes unsubstantiated claims, the US FDA's division of drug marketing, advertising and communications (DDMAC) said in a warning letter to the company.
You may also be interested in...
US FDA drugs center’s ambitious guidance agenda lists 105 new or revised guidances, most of which carried over from the prior year; new to the list are three guidances each on real-world data and individualized antisense oligonucleotide drug products, and a document focused on demonstrating efficacy with a single adequate and well-controlled trial.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.